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Abstract
Background: Due to the use of organophosphates (OP) as pesticides and the availability of OP-type nerve agents, an
effective medical treatment for OP poisonings is still a challenging problem. The acute toxicity of an OP poisoning is mainly
due to the inhibition of acetylcholinesterase (AChE) in the peripheral and central nervous systems (CNS). This results in an
increase in the synaptic concentration of the neurotransmitter acetylcholine, overstimulation of cholinergic receptors and
disorder of numerous body functions up to death. The standard treatment of OP poisoning includes a combination of a
muscarinic antagonist and an AChE reactivator (oxime). However, these oximes can not cross the blood-brain barrier (BBB)
sufficiently. Therefore, new strategies are needed to transport oximes over the BBB.
Methodology/Principal Findings: In this study, we combined different oximes (obidoxime dichloride and two different HI 6
salts, HI 6 dichloride monohydrate and HI 6 dimethanesulfonate) with human serum albumin nanoparticles and could show
an oxime transport over an in vitro BBB model. In general, the nanoparticulate transported oximes achieved a better
reactivation of OP-inhibited AChE than free oximes.
Conclusions/Significance: With these nanoparticles, for the first time, a tool exists that could enable a transport of oximes
over the BBB. This is very important for survival after severe OP intoxication. Therefore, these nanoparticulate formulations
are promising formulations for the treatment of the peripheral and the CNS after OP poisoning.
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Introduction
The extensive use of organophosphates (OP) as insecticides and
pesticides in agriculture and for suicide attempt causes worldwide
several hundreds of thousands intoxications and fatalities per year
[1,2,3,4,5]. Hereby, mild poisonings are mainly caused by
accidental exposure [4,6,7,8] and severe cases are mostly due to
suicidal use [9,10]. In addition, highly toxic OP such as tabun,
sarin, soman and VX, also known as ‘nerve agents’, are the
deadliest chemical weapons so far. The repetitive use of nerve
agents during military conflicts and by terrorists [11] emphasizes a
lingering threat to the population. Therefore, the necessity still
exists to develop an effective medical treatment for OP poisonings.
The acute toxic effects of OP is mainly due to a progressive
inhibition of acetylcholinesterase (AChE) by phosphylation
(phosphorylation and phosphonylation) of their active serine
center leading to an inactive enzyme species [12,13,14] in the
peripheral as well as the central nervous systems (CNS) [15].
AChE normally regulates the concentration of the neurotransmit-
ter acetylcholine (ACh) [16]. Phosphylation of the active serine site
leads to an accumulation of the synaptic ACh concentration,
followed by overstimulation of cholinergic receptors and disorder
of numerous body functions such as salivation, lacrimation,
tremors, miosis, diarrhea, and, at worst, respiratory difficulties
and death due to anoxia. OP induced brain injury is characterized
by rapid loss of consciousness, seizures, inhibition of the
respiratory centers in the medulla oblongata as well as long-term
behavioral changes in sub-lethal injuries [15]. The pharmacolog-
ical standard treatment of OP poisoning includes a combination of
a muscarinic antagonist, e.g. atropine, and an AChE reactivator
(oxime), e.g. pyridine 2-aldoxime (2-PAM) or obidoxime, to repair
the biochemical lesion by dephosphylating the enzyme and
returning the function of AChE [15]. However, due to the
chemical nature of the oximes and their pharmacokinetic profile
these oximes can hardly cross the blood-brain barrier (BBB) and
do not reach the central compartment in a sufficient manner
[17,18,19,20,21]. Thus, oximes may reactivate phosphylated
AChE at peripheral sites but marginal in the brain. Therefore,
new strategies are needed to transport oximes over the BBB.
The BBB is created by the cerebral endothelial cells which
function as the major exchange interface between the blood and
the brain. Tight Junctions (TJ) close the intracellular space
between the endothelial cells and block the free diffusion of water-
soluble polar substances. The BBB protects the brain from the
peripheral circulation and toxic substances and restricts the
transport of many therapeutically important drugs from the blood
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obstacle for the effective treatment of many brain diseases.
Over the past few years a number of different strategies have
been devised to overcome this barrier such as osmotic opening of
the TJ and the direct surgical administration of drugs into the
brain. However, the most notable progress has been achieved by
the use of nanotechnology. Different polymeric nanoparticles [22]
as well as solid lipid nanoparticles and liposomes have successfully
been used for the transport of drugs across the BBB and into the
brain. It was possible to transport more than 10 different
nanoparticle-bound drugs including doxorubicin, dalargin, loper-
amide, tubocurarin, nerve growth factor with different chemical
properties and pharmacological effects over the BBB. Further-
more, these nanocarriers have not only enhanced the transport of
the drug into the brain, they also protected the active agent from
enzymatic degradation, and they were able to reduce side effects
[23]. The mechanism of the nanoparticulate drug transport over
the BBB has not been fully understood so far and has been
discussed controversially. It has been suggested that nanoparticle
systems exert a generalized toxic effect on the BBB by opening the
TJ and allowing paracellular movement of solutes into the brain
[24]. However, later studies have clearly shown that no toxic
effects occurred, in vivo and in vitro, at normal dosages. These
studies clearly demonstrated that the nanoparticles enable a
transport of drugs over the BBB and that an association of the
drugs with the nanoparticles is a requirement for this transport
[25]. Furthermore, it has been hypothesized that after injection
into the blood stream apolipoproteins are adsorbed onto the
surface of polysorbate 80-coated nanoparticles [26]. Thus, a
number of transport mechanisms for lipoproteins over the BBB
exist [27,28]. The apolipoprotein-modified particles could then
interact with apolipoprotein receptors at the BBB and result in
their endocytotic uptake into endothelium and possibly transcy-
tosis into the brain. This suggestion is supported by the
observation that nanoparticles made of human serum albumin
(HSA) with adsorbed or covalently bound apolipoprotein E [29] or
apolipoprotein AI [30] transported attached drugs equally well
across the BBB [31]. However, running mechanism studies
showed a specific binding and uptake of apolipoprotein-modified
HSA nanoparticles on endothelial cells. Moreover, they are able to
enter the CNS by transcytosis and are delivered to neurons [29].
In the present study, obidoxime dichloride and both HI 6 salts
HI 6 dichloride monohydrate and HI 6 dimethanesulfonate were
bound to biodegradable HSA nanoparticles and the oxime
transport over an in vitro BBB model as well as the reactivation
of OP-inhibited AChE in this model were assessed. The
nanoparticulate transported oximes achieved an even better
reactivation of OP-inhibited AChE than freely diffusing oximes.
Materials and Methods
Nanoparticle preparation and characterization
Preparation of HSA nanoparticles. HSA nanoparticles
were prepared by a desolvation technique previously described by
Langer et al. [32]. Briefly, 200 mg HSA (fraction V; purity 96–99%)
were dissolved in 2.0 ml 10 mM sodium chloride. After pH
adjustment to pH 8.3, the desolvation was performed by drop-wise
addition of 8.0 ml 96% Ethanol under stirring (600 rpm) at room
temperature (RT). To stabilize the particles by crosslinking, 117.5 ml
8% glutaraldehyde were added. After 18 h of constant stirring, the
resulting nanoparticle suspension was purified by centrifugation
(16,1006g, 8 min) and redispersion of the pellet in water.
Recombinant apolipoprotein E (ApoE) (34,200 Da, Biotechnol-
ogy General, Rehovot, Israel) was attached covalently to the
nanoparticles via a bifunctional NHS-PEG-Mal crosslinker
(5,000 Da, RAPP Polymere GmbH, Tu ¨bingen, Germany) which
reacts with amino groups on the surface of the particles as well as
with thiol groups introduced into the ApoE molecule [33].
Therefore, the nanoparticles were centrifuged and redispersed in
phosphate buffer pH 8.0. A ten-fold molar excess of the NHS-
PEG-Mal linker was added to the nanoparticles for the activation
reaction under constant shaking for 1 h at RT. Then, these
activated nanoparticles were purified by centrifugation and
redispersion as described above.
In order to introduce sulfhydryl groups into the apolipoprotein
molecule, ApoE was dissolved in phosphate buffer pH 8.0, and a
50-fold molar excess of 2-iminothiolane was added. This mixture
was incubated for 2 h under constant shaking at RT. The
purification of thiolated apolipoprotein was performed by size
exclusion chromatography with a D-Salt
TM desalting column
(Pierce, Rockford, USA) as previously described by Michaelis et al.
[33]. For the conjugation of the activated nanoparticles with the
thiolated ApoE, 1 ml of thiolated apolipoprotein was added to
1 ml of activated nanoparticles and the mixture was stirred
(650 rpm) for 12 h at RT. These conjugated nanoparticles were
purified as described above. Supernatants were collected to
determine the amount of unbound ApoE by a standard Micro
BCA
TM protein assay (Pierce, Rockford, USA) according to the
manufacturer’s instructions.
As a control, unmodified HSA nanoparticles were associated
with poly-ethylene-glycol (PEG) chains by linking mPEG-SPA-
5000 (Nektar, Huntsville, USA) to the particle surface. The
nanoparticles were incubated with a 50-fold molar excess of
mPEG-SPA-5000 in phosphate buffer pH 8.0 for 1 h under
constant shaking at RT. These PEGylated nanoparticles were
purified as described above.
Drug-loading of the nanoparticles. The nanoparticles
were loaded with the drug by adsorption on particles surface.
The adsorptive drug-loading of the nanoparticles was freshly
performed 1 day before use by adding of the different oxime
solutions (obidoxime dichloride, HI 6 dichloride monohydrate and
HI 6 dimethanesulfonate, respectively) to the nanoparticles. The
adsorption occurred under stirring (650 rpm) at RT over night
and the adsorptive drug-loaded nanoparticles were used directly
for the experiments.
Nanoparticle characterization
The concentration of HSA nanoparticles was determined by
microgravimetry [34].
The mean particle diameter and polydispersity were investigat-
ed by photon correlation spectroscopy (PCS) using a Malvern
Zetasizer 3000 HSA (Malvern Instruments Ltd., Malvern, UK).
Isolation of primary porcine brain capillary endothelial
cells (pBCEC) and cell culture
Isolation of primary porcine brain capillary endothelial
cells (pBCEC). Primary porcine brain capillary endothelial cells
(pBCEC) were isolated according to a modified version of the
method of Zenker et al. [35]. Briefly, fresh porcine skulls were
obtained from the local slaughterhouse (Schlachthof Zweibru ¨cken,
Germany) after routine slaughter. Animals were killed in
accordance to the guideline 93/119/EC of the European
Community on the protection of animals at the time of
slaughter or killing, dated December 22nd, 1993. After opening
of the skullcap cerebral tissues were prepared. The meninges were
removed and the grey matter was collected and minced into small
pieces. pBCEC were isolated by two enzymatic digestion and
centrifugation steps with dispase and collagenase and a further
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vessels and incomplete digested capillary fragments were removed
by filtration through a cell strainer and resting erythrocytes were
lysed.
pBCEC were cultivated on collagen IV-coated flasks, plates or
Transwell systems at 37uC and 5% CO2 in M199 medium,
supplemented with 10% newborn calf serum, 0.7 mM L-
glutamine and antibiotics (penicillin/streptomycin and gentami-
cin). The first medium change to remove debris from attached
cells occurred 1 h and 24 h after plating, if the cells grew on
Transwells or 24 h after plating, if the cells grew on cell culture
flasks or plates. The medium was switched to serum-free medium
(DMEM/F12 with L-glutamine, penicillin/streptomycin, genta-
micin and 550 nM hydrocortisone) after the cells reached
confluence.
Cell culture. Furthermore, the mouse brain endothelioma
cell line bEnd3 (LGC Promochem, Wesel, Germany) was used.
The cells were cultured at 37uC and 5% CO2 in DMEM high
glucose medium, supplemented with 10% fetal calf serum.
Cellular uptake and intracellular distribution of the
nanoparticles
Cellular uptake and intracellular distribution of the nanopar-
ticles were studied by confocal laser scanning microscopy (CLSM).
bEnd3 cells were cultured on collagen IV-coated glass slides and
treated with the different nanoparticle formulations for 4 h at
37uC. After this incubation the cells were washed twice with
serum-free medium and the cytosol was stained with CellTrack-
er
TM Red CMTPX (Invitrogen, Karlsruhe, Germany) as de-
scribed in the manufacturer instructions manual. Cells were fixed
with 0.5–1% PFA for 5–10 min. After fixation the cells were
embedded in Vectashield HardSet Mounting Medium containing
DAPI for cell nuclei staining. The CLSM study was performed
with an Axiovert 200 M microscope with a 510 NLO Meta device
(Zeiss, Jena, Germany), Ti:Sa femtosecond or an argon ion laser
and the LSM Image Examiner software. The green autofluores-
cence of the nanoparticles at 488/520 nm was used here.
Cell viability study
Cell viability was determined in pBCEC using WST-1 assay
(Cell Proliferation Reagent, Roche Diagnostics, Mannheim,
Germany) based upon the absorption measurement of formazan
formation. Briefly, cells were cultured in 96-well plates under the
same conditions as for drug transport study and were incubated
with the different nanoparticulate formulations for 24 h at 37uC.
Afterwards, the cells were washed and the determination of cell
viability was carried out after addition of WST-1 reagent and
formazan measurement, as described in the manufacturer
instructions manual.
Measurement of transendothelial electrical resistance
(TER) and the capacitance (Ccl)
After the isolation of the pBCEC, the cells were seeded on
collagen IV-coated Transwell inserts, which were placed in the
cellZscope (nanoAnalytics, Mu ¨nster, Germany). The transen-
dothelial electrical resistance (TER) and the capacitance (Ccl)o f
the barrier-forming pBCEC were measured automatically every
hour under physiological conditions by impedance measurement
with the cellZscope, which means that the cell module of the
cellZscope is placed inside of the incubator during the experiment
and the external controller is connected to a computer outside of
the incubator. Therefore, there is no influence of temperature
changes or vibration during the TER measurement.
Drug transport study
Preparation of human AChE. Haemoglobin-free eryth-
rocyte ghosts, as a source of membrane-bound human AChE,
were prepared according to Dodge et al. [36] with minor
modifications according to [37]. Briefly, heparinized human
blood was centrifuged, the plasma removed and the erythrocytes
were washed with phosphate buffer (0.1 M, pH 7.4). The packed
erythrocytes were diluted in hypotonic phosphate buffer (6.7 mM,
pH 7.4) to facilitate haemolysis, followed by centrifugation. The
supernatant was removed and the pellet resuspended in phosphate
buffer (0.1 M, pH 7.4), after additional washing cycles. Aliquots of
the erythrocyte ghosts were stored at 280uC until use.
Inhibition of AChE. OP-inhibited AChE was prepared by
incubation of AChE with paraoxon-ethyl or sarin for 15 min at
37uC. The OP excess after inhibition was removed by overnight
dialyses with phosphate buffer (0.1 M, pH 7.4) at 4uC [37]. The
OP-inhibited AChE was stored at 280uC until use.
Enzymatic assay. For drug transport studies the pBCEC were
seeded on collagen IV-coated Transwell inserts directly after isolation.
The cells were incubated with the different nanoparticulate
formulations for 4 h at 37uC by adding the nanoparticles into the
upper/apical compartment of the Transwell system, when the TER
was at the maximum. After 4 h the medium of the lower/basolateral
compartment was collected and the transport of the drug was
measured by the reactivation of OP-inhibited AChE as earlier
described in [37]. Briefly, at 0 min 10 ml aliquots of the inhibited
AChE were transferred to cuvettes containing phosphate buffer
(0.1 M, pH 7.4), 5,59-dithio-bis-2-nitrobenzoic acid (DTNB) and
750 ml of the collected medium, which contains the transported
oxime. After incubating for 15, 30, 45 and 60 min (at 37uC) the AChE
activity was determined spectrophotometrically according to Ellman
et al. [38] by adding acetylthiocholine iodide (ASCh). The assay was
run at 37uC and 412 nm.
Reactivation kinetics. The reactivation of OP-inhibited
AChE proceeds according to the following scheme 1 [37,39]:
EP ½  z Ox ½ 
KD EPOx ½    ?
kr E ½  z POx ½  ð Scheme1Þ
In this scheme [EP] is the phosphylated AChE, [EPOx] the
phosphyl-AChE-oxime complex, [Ox] the reactivator (= oxime),
[E] the reactivated enzyme and [POx] the phosphylated oxime.
KD (= [EP] [Ox]/[EPOx]) is the dissociation constant, which is
inversely proportional to the affinity of the oxime to [EP], and kr
the rate constant for the displacement of the phosphyl-residue
from [EPOx] by the oxime, indicating the reactivity.
In case of a complete reactivation, with [Ox] » [EP]0, a pseudo-first-
order rate equation 1 can be derived for reactivation process [40].
kobs~
kr Ox ½ 
KDz Ox ½ 
ð1Þ
Using a discontinuous method for determination of enzyme
activity after different reactivation times and setting the maximal
reactivation of the enzyme as 100%, kobs values can be calculated
by non-linear regression analysis, applying equation 2:
vt~vc: 1{e{kobs
:t 
ð2Þ
This equation represents the maximal velocity (vc) and the
velocity at time t (vt).
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the transported oxime vc,v i (velocity of the inhibited enzyme) and
vt were measured with the enzymatic AChE-assay and kobs was
calculated according to equation 2. After rearrangement of
equation 1, oxime concentration can be calculated according to
equation 3:
Ox ½  ~
kobs:KD
kr{kobs
ð3Þ
In the experimental set-up for this enzymatic AChE-assay
KD=32.20 and kr=0.81, if obidoxime dichloride is used as
reactivator together with paraoxon-ethyl as inhibitor and
KD=50.10 and kr=0.677, if the HI 6 salts are used as reactivator
together with sarin as inhibitor. The constants were taken from
Worek et al. [37].
For the standardized oxime concentrations the dilution of the
oxime in the cuvette and the Transwell system were taken into
account.
The enhanced oxime-transport using the nanoparticulate
formulations was calculated related to the transported free oximes
and was expressed as transport difference (%).
Statistical analysis was made using the two-tailed Mann-
Whitney U Test, which is equivalent to the Wilcoxon rank sum
test [41,42,43]. Statistical significance was defined at P,0.05
values.
Results and Discussion
Nanoparticle preparation and characterization
The human serum albumin-based nanoparticles were prepared
by a well known desolvation technique previously described by
Langer et al. [32]. The size of the ApoE-modified nanoparticles
was 229.9615.8 nm and the size of the PEGylated nanoparticles
was 217.6614.0 nm. The polydispersity index of all preparations
was smaller than 0.1 demonstrating that monodisperse nanopar-
ticle formulations have been prepared. As shown by Micro
BCA
TM protein assay, 34.065.2% of the initial apolipoprotein
amount was associated with the nanoparticles.
In order to minimize the very time-consuming and cost-
intensive isolation of primary brain capillary endothelial cells
(pBCEC) brain capillary endothelium cell lines, as the bEnd3,
were used for cellular uptake and subcellular distribution studies.
These cell lines still express the appropriate receptors of the BBB,
but they already lost some other characteristics of the BBB, like a
high transendothelial electrical resistance as indications of intact
tight junctions [44,45]. Also primary cells longer cultivated in cell
culture lose their BBB characteristics [46] with the time.
Therefore, cell viability and drug transport studies were done on
freshly isolated primary cells accomplished after measurement of
their transendothelial electrical resistance.
Cellular uptake and subcellular distribution of the
nanoparticles
The specificity of the cellular binding and uptake of the
unloaded ApoE-modified nanoparticles in comparison to the
PEGylated nanoparticles and the optimal incubation time of 4 h
could be evidenced in our former study by Zensi et al. [29].
Therefore, the cellular uptake and intracellular distribution of the
oxime-loaded ApoE-modified or PEGylated nanoparticulate
formulations were exemplarily shown on HI 6 dichloride
monohydrate-loaded nanoparticles by CLSM. bEnd3 cells were
incubated either with 0.26 mg nanoparticles per cm
2 growth area
of the specific ApoE-modified or the corresponding PEGylated
control nanoparticles for 4 h at 37uC (Figure 1). Pictures were
taken within inner sections of the cells. Green fluorescence of
specifically uptaken ApoE-modified nanoparticles was clearly
visible within the inner part of the red stained cytosol (1b) whereas
only some unspecific PEGylated nanoparticles can be detected
(1a). Hence, the previous binding properties of the nanoparticles
detected by FACS could be confirmed.
In summary, the shown CLSM data in combination with the
previous FACS data clarifies the specific binding and intracellular
uptake of the oxime-loaded ApoE-modified nanoparticulate
formulations.
Cell viability study
To exclude any cytotoxic effects of the oxime-loaded nanopar-
ticles and the free oximes on the endothelial cells, the cell viability
Figure 1. Cellular uptake and intracellular distribution of the nanoparticles studied by CLSM. bEnd3 cells were cultured on collagen IV-
coated glass slides and were treated with a) PEGylated HI 6 dichloride monohydrate-loaded nanoparticles or b) ApoE-modified HI 6 dichloride
monohydrate-loaded nanoparticles for 4 h at 37uC. The green autofluorescence of the nanoparticles was used for detection. Red: cytosol stained with
CellTracker
TM Red CMTPX, blue: nucleus stained with DAPI. Pictures were taken within inner sections of the cells.
doi:10.1371/journal.pone.0014213.g001
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nanoparticles and the free drug. All the different nanoparticle
concentrations and oxime concentrations of each oxime (obidox-
ime dichloride and both HI 6 salts HI 6 dichloride monohydrate
and HI 6 dimethanesulfonate) were tested. Therefore, pBCEC
were cultured and incubated for 24 h at 37uC with the different
nanoparticulate formulations under the same conditions and
concentrations as for drug transport studies. Cell viability was
determined using a WST-1 assay based on the absorbance
measurement of formazan formation. The formazan formation is
only possible in the mitochondria of healthy cells, therefore,
untreated cells set the 100% standard. After the incubation with
the oxime-loaded formulations the cells showed more than 100%
formazan formation, meaning that the viability is equal to the
control cells (Figure 2). Therefore, any cytotoxic effect of these
nanoparticulate formulations could be excluded. The formazan
formation of more than 100% compared to the untreated control
cells probably is caused by an activation of the pBCEC after
nanoparticle incubation, visible with both nanoparticlulate
formulations, the ApoE-modified (NP-ApoE) as well as the
PEGylated control-nanoparticles (NP-PEG). This could already
be discovered by our former studies with the unloaded particle
system [29]. In the case of incubation with the free oximes the cell
viability is nearly 100% (between 84.4 and 104.8%), meaning the
free oximes are not toxic for the cells in the used concentration
range (Figure 2).
Measurement of transendothelial electrical resistance
(TER)
Freshly isolated pBCEC are suitable for drug transport studies
in the Transwell system, because micro-vascular endothelial cells
develop also in vitro tight junctions (TJ), which constitute the
integral component of the BBB characteristics. These TJ provide
for a very limited and strongly adjusted material transfer between
blood and brain and thus fulfill the barrier function. Due to the
formation of the TJ in vitro a high transendothelial electrical
resistance (TER) exists, which can be measured together with the
capacitance (Ccl) as indication for an adequate intact cell culture
BBB model. The freshly isolated pBCEC were seeded on collagen
IV-coated Transwell inserts and were cultivated with serous
Figure 2. Cell viability assay. pBCEC were cultured in collagen IV-coated 96-well plates under the same conditions as for drug transport study. The
cells were incubated for 24 h at 37uC with 0.26 mg nanoparticles per cm
2 growth area (0.26 mg NP/cm
2) or 0.52 mg nanoparticles per cm
2 growth
area (0.52 mg NP/cm
2) of the different ApoE-modified (NP-ApoE) as well as the PEGylated (NP-PEG) nanoparticulate formulations, which were loaded
with 100 mM or 1000 mM of obidoxime, HI 6 dichloride monohydrate (HI 6-DCL) or HI 6 dimethanesulfonate (HI 6-DMS). Afterwards, the viability was
determined after addition of WST-1 reagent and measurement of formazan formation, as described in the manufacturer instructions manual.
Untreated cells set the 100% standard.
doi:10.1371/journal.pone.0014213.g002
Figure 3. Measurement of transendothelial electrical resistance (TER) and the capacitance (Ccl). pBCEC were seeded on collagen IV-
coated Transwell inserts, which were placed in the cellZscope. The transendothelial electrical resistance (TER) and the capacitance (Ccl) of the pBCEC
were measured automatically every hour by impedance measurement. As control the measurement of the transendothelial electrical resistance (TER)
of a Transwell insert without cells is shown.
doi:10.1371/journal.pone.0014213.g003
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14213Figure 4. Long time measurement of transendothelial electrical resistance (TER) after nanoparticle addition. pBCEC were seeded on
collagen IV-coated Transwell inserts and incubated with the free drug or 0.26 mg nanoparticles per cm
2 growth area of the ApoE-modified (NP-ApoE)
as well as the PEGylated (NP-PEG) nanoparticulate formulations, which were loaded with 1000 mM of HI 6 dichloride monohydrate (HI 6-DCL) at 37uC
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2 and the TER started
increasing, indicating a confluent monolayer. The medium was
switched to serum-free hydrocortisone (HC)-containing medium
after the cells reached confluence to force further increase of TER
(Figure 3). When the TER reached its maximum and the values
were at least over 300 Vcm
2 the nanoparticle incubation was
started for drug transport studies.
Furthermore, the measurement of the TER can be used for the
valuation of the toxic potential of the nanoparticles on the BBB.
Thus, 0.26 mg nanoparticles per cm
2 growth area of the 1000 mM
HI 6 dichloride monohydrate loaded specific ApoE-modified or
the corresponding PEGylated nanoparticles as well as the free
oxime were added ad the maximum of the TER values to the
pBCEC to study the influence of the nanoparticles and the drug on
the BBB properties (Figure 4). As already known, there is influence
of the in vitro BBB properties by temperature changes or vibration
like the nanoparticle incubation. Therefore, there was a minor
transient break-in during the TER measurement after nanopar-
ticle addition and a recovery of the TER could be observed
(Figure 4). However, the TER remained on a high value, speaking
for closed TJ and in consequence for a transcellular transportation
route. Also, our former studies with the unloaded nanoparticles
confirmed the integrity of the BBB after nanoparticle incubation in
animal tests [29]. Therefore, this experiment supplemented the
cell viability study and confirmed the non-toxicity of the
nanoparticulate formulations.
Drug transport study
For the drug transport studies the pBCEC were cultivated as
described before. The cells were incubated with 0.26 mg or
0.52 mg nanoparticles per cm
2 growth area (0.26 mg or 0.52 mg
NP/cm
2) of the specific ApoE-modified or the corresponding
PEGylated control nanoparticles, which were adsorptively loaded
with 100 mM or 1000 mM of the different oximes (obidoxime
dichloride and the both HI 6 salts HI 6 dichloride monohydrate
and HI 6 dimethanesulfonate). Furthermore, as control the cells
were incubated with free oxime in the same amount as used for
nanoparticle adsorption. After 4 h the medium of the lower/
basolateral compartment was collected and the nanoparticulate
drug transport was measured by the enzymatic AChE-assay as
reactivation of the OP-inhibited AChE (see section 2.6.). The
results, summarized in Tables 1–3, demonstrated that a nano-
particulate-mediated transport of active obidoxime, HI 6 dichlo-
ride monohydrate as well as HI 6 dimethanesulfonate over the in
vitro BBB-model was possible with these nanoparticulate formula-
tions. As expected, the specific ApoE-modified nanoparticles
showed a better reactivation of the OP-inhibited AChE than the
PEGylated control nanoparticles and free oximes, which can not
cross the BBB in a sufficient manner. These findings argue for a
nanoparticle-mediated transport and funneling of the adsorbed
oxime over the BBB model. In all cases taking the standardized
oxime concentration into account, the adsorptive loading with the
higher oxime concentration (1000 mM compared to 100 mM) led
by adding the nanoparticles into the upper/apical compartment of the Transwell system. The TER was measured automatically every hour by
impedance measurement. A magnification of the area of interest is highlighted in the red quadrangle. As control the measurement of the TER of a
Transwell insert without cells is shown.
doi:10.1371/journal.pone.0014213.g004
Table 1. Transport study of adsorptively obidoxime-loaded nanoparticles on an in vitro BBB model.
[NP], [drug-loading] NP-ApoE NP-PEG free obidoxime
standardized
[oxime]
(mM)
transport
difference
(%)
standardized
[oxime]
(mM)
transport
difference
(%)
standardized
[oxime]
(mM)
0.52 mg NP/cm
2, 100 mM 15.06 +39.06 13.01 +20.13 10.83
0.52 mg NP/cm
2, 1000 mM 92.25 +133.49 63.47 +60.64 39.51
0.26 mg NP/cm
2, 100 mM 9.06 232.44 6.92 248.40 13.41
0.26 mg NP/cm
2, 1000 mM 39.22 +123.48 30.42 +73.33 17.55
doi:10.1371/journal.pone.0014213.t001
Table 2. Transport study of adsorptively HI 6 dichloride monohydrate-loaded nanoparticles on an in vitro BBB model.
[NP], [drug-loading] NP-ApoE NP-PEG free HI 6-DCL
standardized
[oxime]
(mM)
transport
difference
(%)
standardized
[oxime]
(mM)
transport
difference
(%)
standardized
[oxime]
(mM)
0.52 mg NP/cm
2, 100 mM 25.76 +41.46 17.41 24.39 18.21
0.52 mg NP/cm
2, 1000 mM 61.81 +136.73 46.22 +77.02 26.11
0.26 mg NP/cm
2, 100 mM 24.96 23.89 5.13 80.25 25.97
0.26 mg NP/cm
2, 1000 mM 67.97 +100.68 26.57 +26.57 33.87
doi:10.1371/journal.pone.0014213.t002
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nanoparticulate packaging with ApoE-modified nanoparticles was
most effective for HI 6 dimethanesulfonate concerning the
enhanced drug transport. Due to the individuality of primary
cells after isolation the results of the drug transport experiments
are normally not suitable to be averaged, as seen on the high
standard deviation in Table 3, were it was exemplarily done once.
Therefore, only the results of single experiments are shown on
Tables 1–3. In the whole of the experiments the advantage of the
ApoE-modified nanoparticles compared to the PEGylated parti-
cles and the free drug had to be recognized.
These results demonstrated the cellular uptake of the specific
ApoE-modified nanoparticles as well as the PEGylated control
nanoparticles. In addition, a nanoparticle-mediated transport of
different oximes over the in vitro BBB model consisting only of
brain capillary endothelial cells was shown. However, a major
difference appears to exist between ApoE-modified and PEGy-
lated nanoparticles: Zensi et al. [29] showed that ApoE-modified
nanoparticles were endocytosed and that they could cross the BBB
in vivo and reached different brain regions, whereas PEGylated
nanoparticles remained at the level of the endothelial cells and
seemed not to penetrate the BBB. Even more importantly,
Michaelis et al. [33] showed in in vivo experiments on mice, that
only ApoE-modified nanoparticles were able to transport phar-
macologically significant amounts of loperamide into the brain,
not the PEGylated particles, whereas loperamide could not cross
the BBB as free drug. Therefore, further in vivo experiments are
needed to prove the transport efficiency of the nanoparticulate
systems presented in this paper. Considering these findings it is
most likely that only the ApoE-modified nanoparticles can
transport a relevant amount of oximes specifically over the BBB.
The above studies demonstrated the proof of concept that a
transport of oximes over a in vitro BBB model with adsorptively
oxime-loaded nanoparticles was possible. Therefore, these parti-
cles could be suitable for the transport of oximes over the BBB,
which is important for survival after OP intoxication. Hence, these
nanoparticulate formulations are promising formulations for the
treatment of the CNS and body after OP poisoning, which has to
be tested in vivo. Furthermore, it has to be studied in vivo if the
attachment of apolipoprotein E (ApoE) is necessary to enable the
oximes to reach the acetylcholinesterase (AChE) sites in the brain.
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